For virologically suppressed adult patients with HIV-1. See Full Indication.

JULUCA | Clinical Trials

Trial Design & Baseline Characteristics

SWORD 1 & 2: Two identically designed, Phase 3 trials in treatment-experienced, virologically suppressed adult patients with HIV-1

View Description

Read more »

Virologic Suppression & Resistance Results

Pooled virologic response and resistance results through 100 weeks

Explore Results

Read more »

Adverse Reactions

Adverse events and rates of discontinuation due to adverse events at 100 weeks    

Learn More

Read more »

Patient-Reported Outcomes

Learn about rates of treatment satisfaction and symptom distress at 100 weeks after switching to JULUCA

View Data  

Read more »

Lipid and Fracture Data and a DEXA Substudy

Learn more about effect on lipids, incidence of fractures, and change in BMD with JULUCA

See Assessments

Read more »

BMD=bone mineral density; DEXA=dual-energy X-ray absorptiometry.